Predicting and monitoring response to head and neck cancer radiotherapy using multimodality imaging and radiobiological digital twin simulations
- PMID: 40378867
- PMCID: PMC12169438
- DOI: 10.1088/1361-6560/add9de
Predicting and monitoring response to head and neck cancer radiotherapy using multimodality imaging and radiobiological digital twin simulations
Abstract
Objective.To predict radiotherapy treatment response for head and neck cancer (HNC) using multimodality imaging and personalized radiobiological modeling.Approach.A mechanistic radiobiological model was combined with multi-modality imaging data from diffusion weighted-magnetic resonance imaging and positron emission tomography scans with [18F]Fluorodeoxyglucose (FDG) and [18F]Fluoromisonidazole (FMISO) tracers to develop personalized treatment response models for human papilloma virus associated HNC patients undergoing chemo-radiotherapy. Models were initialized to incorporate patient-specific imaging and updated to reflect longitudinal measurements of nodal gross tumor volume throughout treatment. Prediction accuracy was assessed based on mean absolute error (MAE) of weekly volume predictions and in predicting locoregional recurrence (LRR) following treatment.Main results.Personalized modeling based on pretreatment imaging significantly improved longitudinal volume prediction accuracy and correlation with measurement compared with a generic population model (MAE = 23.4 ± 10.0% vs 24.9 ± 9.0%,p= 0.002 on pairedt-test,R= 0.82 vs 0.72). Adding volume measurements from weeks 1 and 2 further improved prediction accuracy for subsequent weeks (MAE = 12.5 ± 8.1%, 10.7 ± 9.9%). When incorporating feedback with longitudinal measurements, penalizing large deviations from pretreatment model parameters using a variational regularization method was necessary to maintain model stability. Model-predicted volumes based on baseline + week-1 information significantly improved LRR prediction compared with week-1 volume data alone (area under the curve, AUC = 0.83 vs 0.77,p= 0.03) and was similar to prediction using week-3 volume data (AUC = 0.83 vs 0.85,p= non-significant).Significance.The proposed approach, which integrates clinical imaging and radiobiological principles, could be a basis to guide pretreatment prescription personalization as well as on-treatment adaptations.
Keywords: FDG PET; FMISO PET; diffusion MRI; digital twin; head and neck cancer; quantitative imaging; radiotherapy response.
© 2025 Institute of Physics and Engineering in Medicine. All rights, including for text and data mining, AI training, and similar technologies, are reserved.
Similar articles
-
Use of Diffusion-Weighted Imaging and 18F-Fluorodeoxyglucose Positron Emission Tomography Combined With Computed Tomography in the Response Assessment for (Chemo)radiotherapy in Head and Neck Squamous Cell Carcinoma.Clin Oncol (R Coll Radiol). 2018 Dec;30(12):780-792. doi: 10.1016/j.clon.2018.09.007. Epub 2018 Oct 11. Clin Oncol (R Coll Radiol). 2018. PMID: 30318343
-
Dose painting in radiotherapy for head and neck squamous cell carcinoma: value of repeated functional imaging with (18)F-FDG PET, (18)F-fluoromisonidazole PET, diffusion-weighted MRI, and dynamic contrast-enhanced MRI.J Nucl Med. 2009 Jul;50(7):1020-7. doi: 10.2967/jnumed.109.062638. Epub 2009 Jun 12. J Nucl Med. 2009. PMID: 19525447 Clinical Trial.
-
Changes in serial multiparametric MRI and FDG-PET/CT functional imaging during radiation therapy can predict treatment response in patients with head and neck cancer.Eur Radiol. 2023 Dec;33(12):8788-8799. doi: 10.1007/s00330-023-09843-2. Epub 2023 Jul 5. Eur Radiol. 2023. PMID: 37405500 Free PMC article.
-
Functional imaging early during (chemo)radiotherapy for response prediction in head and neck squamous cell carcinoma; a systematic review.Oral Oncol. 2019 Jan;88:75-83. doi: 10.1016/j.oraloncology.2018.11.005. Epub 2018 Nov 22. Oral Oncol. 2019. PMID: 30616800
-
A new role of PET/CT for target delineation for radiotherapy treatment planning for head and neck carcinomas.Hell J Nucl Med. 2012 May-Aug;15(2):139-43. Hell J Nucl Med. 2012. PMID: 22833861 Review.
References
-
- Pfister DG, Spencer S, Adelstein D, Adkins D, Anzai Y, Brizel DM, et al. Head and neck cancers, version 2.2020. J Natl Compr Canc Netw. 2020. Jul 1;18(7):873–98. - PubMed
-
- van der Laan HP, Van den Bosch L, Schuit E, Steenbakkers RJHM, van der Schaaf A, Langendijk JA. Impact of radiation-induced toxicities on quality of life of patients treated for head and neck cancer. Radiother Oncol. 2021. Jul 1;160:47–53. - PubMed
-
- Osazuwa-Peters N, Simpson MC, Zhao L, Boakye EA, Olomukoro SI, Deshields T, et al. Suicide risk among cancer survivors: Head and neck versus other cancers. Cancer. 2018. Oct 15;124(20):4072–9. - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical